Dawn Zacharias, MD
Allergy & Immunology · Westlake, OHNPI 1609853183
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,525 of the $15,289 with a category attached, or 62.3%. 21 manufacturers reported payments, led by CSL Behring at 47.5% of the total. 2025 is the largest year on record at $11,350, more than ten times the $571 reported in 2019.
Across 110 payments — averaging $138.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$7K
- Novartis$3K
- AstraZeneca$2K
- Blueprint Medicines Corporation$611
- GSK$447
- ADMA Biomanufacturing LLC$332
- plus $1K from 15 others
What the payments were for
- Consulting fees$9,52562%
- Food & beverage$5,51936%
- Education$2452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 6 | $7,264 |
| Novartis | 9 | $2,912 |
| AstraZeneca | 31 | $2,223 |
| Blueprint Medicines Corporation | 8 | $611 |
| GSK | 21 | $447 |
| ADMA Biomanufacturing LLC | 4 | $332 |
| Optinose US, Inc. | 5 | $330 |
| Regeneron Healthcare Solutions, Inc. | 5 | $282 |
| Genentech USA, Inc. | 4 | $209 |
| Sanofi | 1 | $125 |
| Phadia US Inc. | 1 | $117 |
| Galderma Laboratories, L.p. | 2 | $109 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $62 |
| Pfizer | 2 | $48 |
| Amgen | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Covis Pharma GmbH | 1 | $18 |
| Kaleo, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,289 in reported general payments places this provider in the 80th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 75 | $200,144 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 35 | $191,012 |
| Dupixent PenDupilumab | 48 | $179,837 |
| Dupixent SyringeDupilumab | 34 | $131,839 |
| TezspireTezepelumab-Ekko | 28 | $125,207 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 20 | $79,556 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $53,474 |
| NucalaMepolizumab | 12 | $44,140 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $18,593 |
| XhanceFluticasone Propionate | 15 | $17,383 |
| DuleraMometasone/Formoterol | 45 | $16,801 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $15,249 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $14,698 |
| Spiriva RespimatTiotropium Bromide | 28 | $14,073 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $12,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Cuvitru | $34 | $270,56855 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $2,223 | $155,15481 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $447 | $121,293132 claims |
| Optinose US, Inc.Xhance | $330 | $17,38315 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $14 | $4,49615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 128 allergy & immunology providers in Ohio.
Other allergy & immunology in Westlake
- Justin GreiweCincinnati$1M
- Jonathan BernsteinCincinnati$810K
- Adam UpdegraffToledo$379K
- Syed RehmanToledo$374K
- Gordon MyersCincinnati$346K
- Nancy Wasserbauer KingstonRocky River$256K
- David LangCleveland$251K
- James FernandezCleveland$179K
- Donald McNeilColumbus$136K
- Amber PattersonFindlay$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.